Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    mesothelioma AND West Virginia
Show Display Options
Rank Status Study
1 Completed PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
Condition: Malignant Mesothelioma
Intervention: Drug: PTK787/ZK 222584
2 Recruiting Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Condition: Mesothelioma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin
3 Completed An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
Condition: Malignant Pleural Mesothelioma
Interventions: Drug: MORAb-009 (Amatuximab);   Drug: Pemetrexed;   Drug: Cisplatin
4 Terminated A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Condition: Solid Organ Tumors
Intervention:
5 Unknown  S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
Condition: Malignant Mesothelioma
Intervention: Drug: everolimus
6 Active, not recruiting Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Conditions: Advanced Malignant Mesothelioma;   Epithelioid Mesothelioma;   Recurrent Malignant Mesothelioma;   Sarcomatoid Mesothelioma
Interventions: Drug: Cediranib Maleate;   Drug: Cisplatin;   Drug: Pemetrexed Disodium;   Other: Placebo
7 Completed
Has Results
Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
Condition: Mesothelioma
Interventions: Drug: pemetrexed disodium;   Drug: gemcitabine hydrochloride;   Drug: carboplatin
8 Completed Collecting Tumor Samples From Patients With Gynecological Tumors
Conditions: Borderline Ovarian Clear Cell Tumor;   Borderline Ovarian Serous Tumor;   Cervical Adenocarcinoma;   Cervical Adenosquamous Carcinoma;   Cervical Small Cell Carcinoma;   Cervical Squamous Cell Carcinoma, Not Otherwise Specified;   Childhood Embryonal Rhabdomyosarcoma;   Childhood Malignant Ovarian Germ Cell Tumor;   Endometrioid Stromal Sarcoma;   Gestational Trophoblastic Tumor;   Malignant Mesothelioma;   Malignant Ovarian Epithelial Tumor;   Melanoma;   Neoplasm of Uncertain Malignant Potential;   Ovarian Brenner Tumor;   Ovarian Clear Cell Cystadenocarcinoma;   Ovarian Serous Cystadenocarcinoma;   Paget Disease of the Vulva;   Recurrent Cervical Carcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Ovarian Germ Cell Tumor;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma;   Recurrent Vaginal Carcinoma;   Recurrent Vulvar Carcinoma;   Stage I Ovarian Cancer;   Stage I Uterine Corpus Cancer;   Stage I Vaginal Cancer;   Stage I Vulvar Cancer;   Stage IA Cervical Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IA Ovarian Germ Cell Tumor;   Stage IB Cervical Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IB Ovarian Germ Cell Tumor;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IC Ovarian Germ Cell Tumor;   Stage II Ovarian Cancer;   Stage II Uterine Corpus Cancer;   Stage II Vaginal Cancer;   Stage II Vulvar Cancer;   Stage IIA Cervical Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIA Ovarian Germ Cell Tumor;   Stage IIB Cervical Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIB Ovarian Germ Cell Tumor;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIC Ovarian Germ Cell Tumor;   Stage III Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage III Cervical Cancer;   Stage III Uterine Corpus Cancer;   Stage III Vaginal Cancer;   Stage III Vulvar Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Ovarian Germ Cell Tumor;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Ovarian Germ Cell Tumor;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Borderline Ovarian Surface Epithelial-Stromal Tumor;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Stage IV Uterine Corpus Cancer;   Stage IVA Cervical Cancer;   Stage IVA Vaginal Cancer;   Stage IVB Cervical Cancer;   Stage IVB Vaginal Cancer;   Stage IVB Vulvar Cancer;   Uterine Corpus Cancer;   Uterine Corpus Leiomyosarcoma;   Vulvar Squamous Cell Carcinoma
Intervention: Other: Laboratory Biomarker Analysis
9 Active, not recruiting LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition: Tumors With CDK4/6 Pathway Activation
Intervention: Drug: LEE011

Study has passed its completion date and status has not been verified in more than two years.